List of Next-Gen Sequencing Companies in United Kingdom - 19

AMPLY Discovery is a Belfast-based techbio company that deploys machine learning and synthetic biology to mine vast biological data to discover novel drug and nutraceutical candidates. Their technology digitizes life's diversity, using next-gen sequencing for drug discovery to tackle complex diseases such as cancer, metabolic disease, and infectious diseases through AI (artificial intelligence). They have raised over €1.6 million in grant funding from Innovate UK to develop their drug discovery platform.

Bactobio is a London-based biotechnology company that uses synthetic biology, next-generation sequencing, and machine learning to culture the 99% of microbes which have previously been unculturable. Our exclusive access to nature's greatest bioresource allows us to discover novel chemical and biological products in both healthcare and agriculture. Our first targets are to discover novel antibiotics against the worst bacterial infections and help make plant protection sustainable.

At Biofortuna we form unique partnerships with the most innovative healthcare and life science companies and work together to enhance health and wellbeing all over the world. Our services are wide-ranging, and whether we are supporting diagnostic companies, food safety experts or life science specialists our objectives are the same; to form long term partnerships and become a valued extension of your team. We do that by solving problems and presenting opportunities. We listen to your requirements, develop customised solutions and deliver them with openness and transparency. Operating from state-of-the art, purpose built premises, and benefiting from ISO 13485 certification, ISO 17025 accreditation and FDA registration, we have a proven track record in the development and large-scale manufacture of PCR and LAMP molecular assays and immunoassays.

Broken String Bioscience’s technology platform, INDUCE-seq™, supports the development of cell and gene therapies that are safer by design. INDUCE-seq™, is an NGS-based DNA break mapping platform that enables companies developing cell and gene therapies to measure and quantify the specificity of off-target genetic edits and evaluate the associated genetic outcomes. The platform provides data-driven, actionable insights across the discovery, pre-clinical and clinical development stages to advance gene editing programs

Starting with a vision to truly take paternity testing to the general public, Complement Genomics has been bringing forward new DNA testing services since 2000. Working in areas as diverse as clinical trials and non-human DNA testing, the highly trusted company has considerable expertise in pharmacogenetics. Complement Genomics also provides COVID-19 testing for private clients and businesses. Operating from the Durham Genome Centre, Complement Genomics has developed different brands according to the market segment: - dadcheck®gold - DNA testing services for professionals, including solicitors, barristers, local authorities and social services - dadcheck®silver - a full range of DNA testing services for the general public, including paternity and other human relationships, for the determination of parentage, for immigration DNA tests or for DNA tests which are suitable for other legal purposes - Chxout - services designed to serve the non-human DNA testing market – for citizen scientists and professionals alike. Bat Species Identification | Bird Sexing | Bird Species Identification | Bird Parentage | DNA Barcoding of animals, plants and fungi - Geneblitz - designed to serve the CRO and pharmaceutical sector with genotyping and phenotyping for clinical trials - That DNA Company - an online value brand providing DNA testing services, primarily paternity tests, for the general public

At Crane Biosciences, we enable RNA treatments for incurable diseases. We are based at Imperial College London and backed by Norrsken, InnovateUK, Entrepreneur First, and Creative Destruction Lab (University of Oxford).

Cytocell is a biotechnology company that specializes in designing and manufacturing a variety of fluorescence in situ hybridisation (FISH) probes.

Yourgene Health is a leading integrated technologies and services business, enabling the delivery of genomic medicine. Yourgene works in partnership with global leaders in DNA technology to advance diagnostic science. Yourgene primarily develops, manufactures, and commercialises simple and accurate molecular diagnostic solutions, for reproductive health, precision medicine and infectious diseases. Flagship in vitro diagnostic products include Non-Invasive Prenatal Tests (NIPT) for Down’s Syndrome and other genetic disorders, Cystic Fibrosis screening tests, invasive rapid aneuploidy tests and DPYD genotyping. Yourgene has a range of innovative DNA sample preparation platforms, powered by Ranger® Technology, the LightBench® and the LightBench® Detect instruments are ideal for cell-free DNA applications in NIPT, gene synthesis and oncology, including liquid biopsy. Yourgene Genomic Services is a global laboratory service network equipped to be a full life-cycle partner for clinical, research and pharmaceutical organisations to support partners at the preclinical, clinical, and post-market stages to develop, manufacture, obtain regulatory approval and commercialise new products and services. Yourgene Health is headquartered in Manchester, UK with facilities in Singapore, the US and Canada. Yourgene is now part of the Novacyt group of companies. For more information visit www.yourgenehealth.com

Enigma Diagnostics is a PCR-based testing out of the laboratory with a range of simple-to-use products.

Esox Biologics utilises their extensive knowledge of the aquatic microbiome to provide disease prevention solutions that help improve livestock health and welfare.

We are a molecular diagnostics company working predominantly in the fields of infectious disease, cancer diagnostics and personalised medicine. Our ethos is to offer robust easy-to-use, sensitive, and affordable molecular diagnostics technologies and products to researchers, clinicians and drug companies to enable accurate diagnosis and the delivery of safe and effective medicines. Our patented technologies allow for simultaneous detection of multiple targets in one reaction. If you have a project or collaboration in mind, we'd love to hear from you! Do you have a requirement for detecting multiple targets? Are you working with bacteria, viruses or fungus? We can help you achieve what you need with our dedicated team of experts. Drop us a line here or email us at info@genefirst.com

Juno Bio is studying the vaginal microbiome and its impact on women’s health and fertility. Women can purchase sampling kits, take a sample at home, and send it to Juno Bio where theywill analyze the DNA and return the results.

Mogrify® has developed a proprietary suite of platform technologies that utilize a systematic big-data approach to direct cellular reprogramming (Rackham et al., Nature Genetics, 2016) and the maintenance of cell identity (Kamaraj et al., Cell Systems, 2020). The platforms, MOGRIFY® and epiMOGRIFY®, developed over a 12-year period via a multi-national research collaboration, deploy next-generation sequencing, gene regulatory and epigenetic network data to enable the prediction of the transcription factors and growth factors required to produce any target human cell type from any source human cell type. Mogrify is applying its proprietary and award-winning platforms to generate the functional cell types required to transform the lives of patients, by delivering a novel class of in vivo reprogramming therapies across ophthalmology, otology, metabolic and other areas of degenerative disease. Uniquely positioned to address a regenerative medicine market estimated to be worth $150 billion USD by 2028, Mogrify is commercializing its technology via a combination of in vivo reprogramming therapy development, co-development partnerships, as well as the exploitation of the platform in other therapeutic and non-therapeutic applications. Based in Cambridge, UK, the Company has raised over $40 million USD funding from Parkwalk, Ahren Innovation Capital, 24Haymarket, Trend Investment Group, Dr. Darrin M. Disley, OBE, Dr. Jonathan Milner and the University of Bristol Enterprise Fund III, as well as strategic investors; Astellas Venture Management.

As a leading global provider of diagnostic genomic solutions, our goal is to enable researchers and clinical decision makers to reach the right decisions for each patient, every time. The quality and innovation built into our products for NGS, arrays and FISH reflects our commitment to improving the future of genetic clinical care. We offer partnership and collaboration to our customers at every stage of their work.

Our goal is to enable the analysis of anything, anywhere, by anyone. We have developed the world's first and only nanopore DNA and RNA sequencing platform. It's a new generation of sequencing technology — the only one to offer: scalability to portable or ultra-high throughput formats, real-time data delivery, and the ability to elucidate rich biological data. We are aiming to disrupt the way that biological analyses are currently performed, and open up new applications that have a profound, positive impact on society. Our devices offer real-time analysis, for rapid insights, in fully scalable formats — from pocket to population scale — and the technology is being used in more than 100 countries worldwide. Founded in 2005 as a spin-out from the University of Oxford, the company now employs more than 600 people from multiple disciplines including nanopore science, molecular biology and applications, informatics, engineering, electronics, manufacturing and commercialisation. The management team, led by CEO Dr Gordon Sanghera, has a track record of delivering disruptive technologies to the market.

PhoreMost is building a pipeline of novel drug discovery programmes aimed at addressing a range of diseases, with a mission to accelerate, diversify and rationalise drug discovery. Using this core expertise to open up new ‘druggable’ target space and working with a global network of co-invested academic and industrial collaboration partners, we aim to bring a wide array of novel ‘targeted’ therapies more efficiently to market and pass these cost savings onto patients.

Source BioScience, comprised of Source LDPath and Source Genomics, provides industry-leading laboratory services in Genomics and Histopathology, partnering with biotechnology, pharmaceutical, healthcare and academia. Source LDPath provides an end-to-end clinical diagnostic service, from histopathology, including digital pathology and AI, through to molecular diagnostic services. Source LDPath already supports over 85 NHS Trusts and a comprehensive network of Private Healthcare clinics to expand their diagnostic capabilities, ensuring diagnostic results are delivered within clinically actionable timeframes. Source LDPath brings pioneering expertise in digital pathology and AI implementation, helping NHS pathology departments digitise their workflows for streamlined operations and greater diagnostic reporting capacity, tailoring integration touchpoints to the specific requirements of the Hospital or Trust. • Cellular and digital pathology wet laboratory processing • Reporting - access a pool of over 200 specialist consultant pathologists • MDM and Second Opinions • Digital Implementation Support with AI integration • Connectivity and LIMS integration with Source HIVE™ Source Genomics provides a broad portfolio of multi-omic services, delivering high-quality data in Genomics, Spatial Transcriptomics, Proteomics and Epigenomics. Market-leaders in Sanger Sequencing and Next-Generation Sequencing Services, Source Genomics delivers bespoke laboratory expertise to excel your project at rapid turnaround times. • Sanger Sequencing • NGS - WGS, WES, RNA-seq • Oxford Nanopore Sequencing • Olink proteomics • Optical Genome Mapping • 10x Genomics Visium • Bioinformatics • And more Contact us today at enquiries@sourcebioscience.com.

Wobble Genomics specializes in maximizing RNA and DNA sequencing efficiency for the discovery and detection of nucleic acid biomarkers. The company has raised significant investment to accelerate biotechnology innovations and has a team of 10 employees.

Yourgene Health (formerly Premaitha) develops molecular diagnostic products that will have a positive impact on human health and is currently focused in the field of prenatal screening.